Mirum Pharmaceuticals (MIRM) Competitors $75.19 -0.80 (-1.05%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MIRM vs. ASND, VTRS, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Mirum Pharmaceuticals vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership. Is ASND or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Mirum Pharmaceuticals -13.65%-24.76%-8.50% Do analysts rate ASND or MIRM? Ascendis Pharma A/S presently has a consensus price target of $244.36, suggesting a potential upside of 25.74%. Mirum Pharmaceuticals has a consensus price target of $74.44, suggesting a potential downside of 0.99%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has more volatility & risk, ASND or MIRM? Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Does the media prefer ASND or MIRM? In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 12 mentions for Mirum Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.30 beat Mirum Pharmaceuticals' score of 0.95 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, ASND or MIRM? Mirum Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$490.75M24.24-$409.12M-$5.16-37.66Mirum Pharmaceuticals$336.89M11.21-$87.94M-$1.21-62.14 SummaryAscendis Pharma A/S beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRM vs. The Competition Export to ExcelMetricMirum PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.79B$3.14B$5.77B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-62.3821.4074.4425.99Price / Sales11.21298.78465.6391.46Price / CashN/A45.3337.0859.91Price / Book16.009.6012.216.30Net Income-$87.94M-$53.32M$3.28B$270.75M7 Day Performance-1.14%0.53%1.21%3.36%1 Month Performance16.18%9.17%7.52%6.51%1 Year Performance82.81%12.80%63.84%27.98% Mirum Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRMMirum Pharmaceuticals3.2009 of 5 stars$75.19-1.1%$74.44-1.0%+81.3%$3.79B$336.89M-62.38140Analyst ForecastASNDAscendis Pharma A/S3.1082 of 5 stars$205.22-0.3%$244.36+19.1%+75.0%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.5982 of 5 stars$10.48-0.2%$10.40-0.8%-10.3%$12.24B$14.74B-3.6132,000Positive NewsRDYDr. Reddy's Laboratories2.4707 of 5 stars$14.27-0.5%$16.95+18.8%-7.1%$11.97B$3.81B21.6127,811Positive NewsQGENQIAGEN4.468 of 5 stars$47.62+0.1%$49.69+4.4%+3.3%$10.57B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.3393 of 5 stars$54.29+1.7%$63.35+16.7%+87.9%$10.20B$221.90M-13.27400Positive NewsAnalyst ForecastMRNAModerna4.5104 of 5 stars$24.83-1.2%$42.88+72.7%-68.1%$9.78B$3.24B-3.305,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1761 of 5 stars$106.300.0%$109.00+2.5%+252.9%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.6536 of 5 stars$19.02+3.2%$17.33-8.9%+29.8%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences2.8286 of 5 stars$12.91-0.1%$16.38+26.8%+16.4%$8.82B$29.05M-18.44860News CoverageOptions VolumeRVMDRevolution Medicines4.2667 of 5 stars$41.06+1.4%$72.00+75.4%+11.0%$7.57B$11.58M-9.12250Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors QIAGEN Competitors BridgeBio Pharma Competitors Moderna Competitors Verona Pharma PLC American Depositary Share Competitors Elanco Animal Health Competitors Roivant Sciences Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRM) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
